Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylprednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.78 |
| ▸ | PGR | P06401 | 5/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | AR | P10275 | 2/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.70 |
| ▸ | IL6 | P05231 | 1/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylprednisolone SCHEMBL5507451 | 0.99 | NR3C1 (0.76) | HSD17B10HIF1ANR3C1PGRCYP3A4 | |
| Methylprednisolone SCHEMBL17223638 | 0.95 | NR3C1 (0.70) | HSD17B10HIF1ANR3C1PGRCYP3A4 | |
| Methylprednisolone SCHEMBL4274907 | 0.92 | NR3C1 (0.87) | HSD17B10HIF1ANR3C1PGRCYP3A4 | |
| Methylprednisolone SCHEMBL8902882 | 0.91 | HSD17B10 (0.73) | HSD17B10HIF1ANR3C1PGRCYP3A4 | |
| Prednisone SCHEMBL992150 | 0.91 | HIF1A (0.85) | HSD17B10HIF1ANR3C1PGRCYP3A4 | |
| Methylprednisolone SCHEMBL13046609 | 0.88 | HIF1A (1.00) | HSD17B10HIF1ANR3C1PGRCYP3A4 | |
| Methylprednisolone SCHEMBL12440040 | 0.88 | HIF1A (1.00) | HSD17B10HIF1ANR3C1PGRCYP3A4 | |
| Methylprednisolone SCHEMBL541256 | 0.88 | HIF1A (1.00) | HSD17B10HIF1ANR3C1PGRCYP3A4 | |
| Methylprednisolone SCHEMBL21145528 | 0.88 | HIF1A (1.00) | HSD17B10HIF1ANR3C1PGRCYP3A4 | |
| Methylprednisolone SCHEMBL5084 | 0.88 | HIF1A (1.00) | HSD17B10HIF1ANR3C1PGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| CN-111479574-B | Compounds for the treatment and prevention of extracellular histone mediated pathologies | 澳大利亚国立大学 | 2024-02-09 | — | — | CN | disclosed |
| CN-117462563-A | Compounds for the treatment and prevention of extracellular histone mediated pathologies | 澳大利亚国立大学 | 2024-01-30 | — | — | CN | disclosed |
| CN-117427084-A | Compounds for the treatment and prevention of extracellular histone mediated pathologies | 澳大利亚国立大学 | 2024-01-23 | — | — | CN | disclosed |
| US-20220177574-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| CN-113473992-A | Compounds for the treatment and prevention of complications associated with neutrophil extracellular traps | 澳大利亚国立大学 | 2021-10-01 | — | — | CN | disclosed |
| EP-1843751-B1 | PHARMACEUTICAL LIPID COMPOSITIONS | CAMURUS AB (SE) | 2020-09-30 | — | — | EP | disclosed |
| US-20200131265-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20190218288-A1 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof | MACROGENICS, INC. (US) | 2019-07-18 | — | — | US | disclosed |
| CN-103717619-B | Treat the anti-KIR antibodies of inflammation and autoimmune disease | 因内特制药股份有限公司 | 2018-11-13 | — | — | CN | disclosed |
| WO-2005115452-A2 | FCϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050260213-A1 | Fcgamma-RIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2005-11-24 | — | — | US | disclosed |
| WO-2005110474-A2 | HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050215767-A1 | Fcgamma riib specific antibodies and methods of use thereof | MACROGENICS INC. | 2005-09-29 | — | — | US | disclosed |
| EP-1534335-A2 | FCGAMMARIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005018669-A1 | FCϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040185045-A1 | FcgammaRIIB-specific antibodies and methods of use thereof | MACROGENICS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004016750-A2 | FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | MACROGENICS, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| US-6265439-B1 | Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives | G.D. SEARLE & CO. | 2001-07-24 | — | — | US | disclosed |
| US-5451604-A | Useful in organ transplant surgery | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885HSD17B10 3010/4885HIF1A 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.